C3 and lung carcinoma: However, it has been shown that targeting the complement pathway has been successful as a therapeutic treatment option for lung cancer in a few pre-clinical studies which indicate that inhibition of either C3a or C5a signaling inhibits cancer progression in lung cancer models and other malignancies[45].